October 17, 2008

TROP2 expression as prognostic marker for gastric carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Results show that TROP2 is an independent prognostic marker for disease recurrence in intestinal type gastric cancer. Due to its wide distribution TROP2 may become an attractive therapeutic target in a subgroup of patients with gastric cancer.

Bookmark

Cite This Study

Mühlmann et al. (Fri,) studied this question.

synapsesocial.com/papers/69da9ab200ab073a278387fa https://doi.org/https://doi.org/10.1136/jcp.2008.060590

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity2007 · 172 citations
2Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting.1990 · 54 citations
3A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma2006 · 21 citations
4Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction2001 · 3,509 citations
5Retroposition in a Family of Carcinoma-Associated Antigen Genes1993 · 35 citations

Bookmark